Janssen releases data on Ph 2a trials of guselkumab and golimumab in ulcerative colitis

Feb 19, 2022

Janssen released data from a Ph 2a clinical trial of guselkumab and golimumab in ulcerative colitis.  Janssen reported that the combination induced higher rates of clinical response, clinical remission, endoscopic improvement and a composite histologic-endoscopic endpoint at 12 weeks that either treatment alone.

Print Page Mail Article